Cargando…

Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment

Several randomized controlled trials have shown a benefit of high-dose intensive statin treatment in reducing risk of death and second cardiovascular disease (CVD) events in patients previously diagnosed with an acute coronary syndrome (ACS). Non-randomized studies in clinical settings support these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rockberg, J., Jørgensen, L., Taylor, B., Sobocki, P., Johansson, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374870/ https://www.ncbi.nlm.nih.gov/pubmed/28373930 http://dx.doi.org/10.1016/j.pmedr.2017.03.001

Ejemplares similares

Diabetes Mellitus and Mortality after Acute Coronary Syndrome as a First or Recurrent Cardiovascular Event
por: Cubbon, Richard M., et al.
Publicado: (2008)

Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study
por: Chinwong, Dujrudee, et al.
Publicado: (2015)

Statin intensity and risk for cardiovascular events after heart transplantation
por: Golbus, Jessica R., et al.
Publicado: (2020)

Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients
por: Schonberger, Robert B., et al.
Publicado: (2020)

Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Long-term risk of death and recurrent cardiovascular events following acute coronary syndromes
por: Gouda, Pishoy, et al.
Publicado: (2021)

Respiratory Polygraphy Patterns and Risk of Recurrent Cardiovascular Events in Patients With Acute Coronary Syndrome
por: Zapater, Andrea, et al.
Publicado: (2022)

Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes
por: Xie, Gaoqiang, et al.
Publicado: (2017)

Statin doses after acute coronary syndrome
Publicado: (2022)

Guideline‐Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome
por: Hammer, Yoav, et al.
Publicado: (2018)

Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
por: Zhu, Ling, et al.
Publicado: (2020)

Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events
por: Loeffen, Rinske, et al.
Publicado: (2016)

Glycaemic variability and risk of adverse cardiovascular events in acute coronary syndrome
por: Zhang, Lei, et al.
Publicado: (2022)

Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data
por: Hallberg, S., et al.
Publicado: (2015)

Vulnerable plaque derived from aspirated thrombi in recurrent acute coronary syndrome with familial hypercholesterolemia despite intensive lipid-lowering statin therapy
por: Natsui, Hiroyuki, et al.
Publicado: (2022)

New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins
por: Choi, Jah Yeon, et al.
Publicado: (2021)

Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States
por: Steen, Dylan L., et al.
Publicado: (2022)

Comparison of the Effects of High-intensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study
por: Kim, Kihyun, et al.
Publicado: (2021)

Predictors of Readmission after the First Acute Coronary Syndrome and the Risk of Recurrent Cardiovascular Events—Seven Years of Patient Follow-Up
por: Bustea, Cristiana, et al.
Publicado: (2023)

The use of statins for the treatment of depression in patients with acute coronary syndrome
por: Kim, S W, et al.
Publicado: (2015)

Risk factors for major adverse cardiovascular events after the first acute coronary syndrome
por: Okkonen, Marjo, et al.
Publicado: (2021)

Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins
por: Morales-Villegas, Enrique C., et al.
Publicado: (2011)

Risk factors for drug-treated major adverse cardio-cerebrovascular events in patients on primary preventive statin therapy: A retrospective cohort study
por: Steenhuis, Dennis, et al.
Publicado: (2023)

Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention
por: Yun, Kyeong Ho, et al.
Publicado: (2011)

The effect of statin therapy on the characteristics of coronary artery disease in patients with acute coronary syndrome
por: Gulin, D, et al.
Publicado: (2013)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

Statin drugs to reduce breast cancer recurrence and mortality
por: Beckwitt, Colin H., et al.
Publicado: (2018)

Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL Study
por: Zamani, Payman, et al.
Publicado: (2013)

Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms
por: Leiva, Orly, et al.
Publicado: (2023)

Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
por: Zhou, Xiao-hong, et al.
Publicado: (2020)

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol
por: Gao, Jing, et al.
Publicado: (2021)

Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins
por: Berglind, Ingegärd Anveden, et al.
Publicado: (2015)

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL‐ACS Data
por: Lewek, Joanna, et al.
Publicado: (2023)

Statin Discontinuation and Cardiovascular Events Among Older People in Denmark
por: Thompson, Wade, et al.
Publicado: (2021)

Statin use and incident cardiovascular events in renal transplant recipients
por: Anderson, Josephine L. C., et al.
Publicado: (2021)

Risk of recurrent cardiovascular events in coronary artery disease patients with Type D personality
por: Torgersen, Kristin Stensland, et al.
Publicado: (2023)

GRACE (the Global Registry of Acute Coronary Events): the real world side of the cardiovascular clinical practice in acute coronary syndromes
por: Knobel, M, et al.
Publicado: (2001)

Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome
por: Watanabe, Erisa, et al.
Publicado: (2015)

Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency
por: Chinwong, Dujrudee, et al.
Publicado: (2015)

Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome
por: Im, Jihaeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oshuctib4it3s8h3qecvajmtv5